A Study of AK112 in Advanced Malignant Tumors

• Status: Recruiting
• Trial end date: 2024-01-25

Summary

Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK112 (anti-PD-1 and VEGF bispecific antibody) combined with AK117（Anti-CD47 Antibody）with or without chemotherapy in advanced malignant tumors

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Akeso